CLL
Approved in relapsed CLL in combination with rituximab where rituximab alone is appropriate due to comorbidities

ZYDELIG®
Patient Profiles

Consider ZYDELIG for elderly patients with comorbidities

Patient With Prior BR,
R Monotherapy
elderly male relapsed chronic lymphocytic leukemia (CLL) patient elderly male relapsed chronic lymphocytic leukemia (CLL) patient

Profile and photo are representative of patients in clinical trials but are not actual cases. For illustrative purposes only.

History

History

  • 70-year-old male
  • History of pulmonary embolism
  • Takes pioglitazone for type 2 diabetes

Diagnosis

Diagnosis

2012, Rai stage III CLL

  • 70% bone marrow involvement

Prior
therapies

Prior therapies

Treated with first-line BR

  • Achieved PR, which lasted 2 years
  • Developed grade 3 anemia and neutropenia due to BR

Treated with R monotherapy in second line

  • Achieved PR, which lasted 9 months

Current
presentation

Current presentation

  • Worsening fatigue, lymph nodes have enlarged
  • ALC increased to 32 x 109/L
  • CBC reveals cytopenias
    • Grade 3 anemia: hemoglobin, 8.0 g/dL
    • Grade 2 thrombocytopenia: platelets, 70 x 109/L
    • Grade 1 neutropenia: ANC, 1.6 x 109/L
  • Across clinical trials, ZYDELIG had similar efficacy in patients aged ≥65 years and in younger patients
    • Older patients had a higher incidence of discontinuation due to AEs, serious AEs, and death
Patient With Prior FCR Therapy and Moderate Renal Impairment
elderly female relapsed chronic lymphocytic leukemia (CLL) patient elderly female relapsed chronic lymphocytic leukemia (CLL) patient

Profile and photo are representative of patients in clinical trials but are not actual cases. For illustrative purposes only.

History

History

  • 61-year-old female
  • Good performance status
  • Has hypertension

Diagnosis

Diagnosis

2006, Rai stage I CLL

  • Elevated ALC
  • Enlarged axillary lymph nodes
  • Asymptomatic

Prior
therapies

Prior therapies

Treated with first-line FCR, 4 years after diagnosis

  • Achieved PR, which lasted 17 months

Current
presentation

Current presentation

  • Developed night sweats, worsening fatigue
  • ALC, 25 x 109/L
  • CBC
    • Hemoglobin, 8.5 g/dL
  • Moderate renal impairment, hypertension, anemia
    (CIRS score of 7)

AE=adverse event; ALC=absolute lymphocyte count; ANC=absolute neutrophil count; BR=bendamustine, rituximab; CBC=complete blood count; CIRS=Cumulative Illness Rating Scale; CLL=chronic lymphocytic leukemia; FCR=fludarabine, cyclophosphamide, rituximab; PR=partial response; R=rituximab.